Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir)

Molecular Pharmacology

Volumn 84, Issue 4, 2013, Pages 615-629

  Naesens, Lieve ^a   Guddat, Luke W ^b   Keough, Dianne T ^b   Van Kuilenburg, André B P ^c   Meijer, Judith ^c   Vande Voorde, Johan ^a   Balzarini, Jan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE PHOSPHORIBOSYLTRANSFERASE; FAVIPIRAVIR; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PURINE NUCLEOSIDE PHOSPHORYLASE; RIBONUCLEOPROTEIN; T 1105; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; ENZYMATIC ASSAY; GENE SILENCING; HUMAN; HUMAN CELL; INFLUENZA VIRUS; KIDNEY CELL; METABOLITE; PRIORITY JOURNAL;

AMIDES; ANIMALS; ANTIVIRAL AGENTS; CRYSTALLOGRAPHY, X-RAY; DOGS; HEK293 CELLS; HUMANS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MADIN DARBY CANINE KIDNEY CELLS; PYRAZINES;

EID: 84884693953     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.087247     Document Type: Article

References (52)

1. Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, and Grosse-Kunstleve RW et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66:213-221.
2. Allen IC, Pace AJ, Jania LA, Ledford JG, Latour AM, Snouwaert JN, Bernier V, Stocco R, Therien AG, and Koller BH (2006) Expression and function of NPSR1/GPRA in the lung before and after induction of asthma-like disease. Am J Physiol Lung Cell Mol Physiol 291:L1005-L1017. (Pubitemid 44772063)
3. Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, Webster RG, and Govorkova EA (2013) T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol 87:3741-3751.
4. Burgos ES, Ho MC, Almo SC, and Schramm VL (2009) A phosphoenzyme mimic, overlapping catalytic sites and reaction coordinate motion for human NAMPT. Proc Natl Acad Sci USA 106:13748-13753.
5. Chen TR (1983) Chromosome changes in 6-TG-resistant mutant strains derived from a karyotypically stable human line, C32. Cytogenet Cell Genet 35:181-189.
6. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, Andino R, and Cameron CE (2000) The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 6:1375-1379. (Pubitemid 32001022)
7. De Bolle L, Michel D, Mertens T, Manichanh C, Agut H, De Clercq E, and Naesens L (2002) Role of the human herpesvirus 6 u69-encoded kinase in the phosphorylation of ganciclovir. Mol Pharmacol 62:714-721. (Pubitemid 36329391)
8. Eads JC, Scapin G, Xu Y, Grubmeyer C, and Sacchettini JC (1994) The crystal structure of human hypoxanthine-guanine phosphoribosyltransferase with bound GMP. Cell 78:325-334. (Pubitemid 24241099)
9. Emsley P, Lohkamp B, Scott WG, and Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66:486-501.
10. Furuta Y and Egawa H (2001), inventors, Toyama Chemical, assignee. Nitrogenous heterocyclic carboxamide derivatives or salts thereof and antiviral agents containing both. European patent EP1112743A1. 2001 July 4.
11. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, and Watanabe Y et al. (2002) In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 46:977-981. (Pubitemid 34260339)
12. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, and Shiraki K (2005) Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 49:981-986. (Pubitemid 40327713)
13. Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, and Morrey JD (2009) T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 82:95-102.
14. Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, Bailey KW, Furuta Y, and Sidwell RW (2007) In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 51:3168-3176. (Pubitemid 350067524)
15. Hayden F (2009) Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 48 (Suppl 1):S3-S13.
16. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, and Webster RG (2000) A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci USA 97:6108-6113. (Pubitemid 30367531)
17. Jinnah HA, De Gregorio L, Harris JC, Nyhan WL, and O'Neill JP (2000) The spectrum of inherited mutations causing HPRT deficiency: 75 new cases and a review of 196 previously reported cases. Mutat Res 463:309-326.
18. Johnson MA and Fridland A (1989) Phosphorylation of 2′,3′- dideoxyinosine by cytosolic 5′-nucleotidase of human lymphoid cells. Mol Pharmacol 36:291-295. (Pubitemid 19218798)
19. Julander JG, Shafer K, Smee DF, Morrey JD, and Furuta Y (2009) Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother 53:202-209.
20. Kabsch W (2010) XDS. Acta Crystallogr D Biol Crystallogr 66:125-132.
21. Kao RY, Yang D, Lau LS, Tsui WH, Hu L, Dai J, Chan MP, Chan CM, Wang P, and Zheng BJ et al. (2010) Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol 28:600-605.
22. Keough DT, Brereton IM, de Jersey J, and Guddat LW (2005) The crystal structure of free human hypoxanthine-guanine phosphoribosyltransferase reveals extensive conformational plasticity throughout the catalytic cycle. J Mol Biol 351:170-181. (Pubitemid 40967063)
23. Keough DT, Skinner-Adams T, Jones MK, Ng AL, Brereton IM, Guddat LW, and de Jersey J (2006) Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases. J Med Chem 49:7479-7486. (Pubitemid 44913406)
24. Keough DT, Hocková D, Holý A, Naesens LM, Skinner-Adams TS, de Jersey J, and Guddat LW (2009) Inhibition of hypoxanthine-guanine phosphoribosyltransferase by acyclic nucleoside phosphonates: a new class of antimalarial therapeutics. J Med Chem 52:4391-4399.
25. Keough DT, Špaček P, Hocková D, Tichý T, Vrbková S, Slavětínská L, Janeba Z, Naesens L, Edstein MD, and Chavchich M et al. (2013) Acyclic nucleoside phosphonates containing a second phosphonate group are potent inhibitors of 6-oxopurine phosphoribosyltransferases and have antimalarial activity. J Med Chem 56:2513-2526.
26. Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, Le QM, Ozawa M, Furuta Y, and Kawaoka Y (2010) T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci USA 107:882-887.
27. Martínez-Sobrido L and García-Sastre A (2010) Generation of recombinant influenza virus from plasmid DNA. J Vis Exp 42:2057.
28. Masino SA, Li T, Theofilas P, Sandau US, Ruskin DN, Fredholm BB, Geiger JD, Aronica E, and Boison D (2011) A ketogenic diet suppresses seizures in mice through adenosine A? receptors. J Clin Invest 121:2679-2683.
29. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, and Read RJ (2007) Phaser crystallographic software. J Appl Cryst 40:658-674. (Pubitemid 47080256)
30. Mehellou Y, Balzarini J, and McGuigan C (2009) Aryloxy phosphoramidate triesters: a technology for delivering monophosphorylated nucleosides and sugars into cells. ChemMedChem 4:1779-1791.
31. Meier C and Balzarini J (2006) Application of the cycloSal-prodrug approach for improving the biological potential of phosphorylated biomolecules. Antiviral Res 71:282-292. (Pubitemid 44223763)
32. Meneghesso S, Vanderlinden E, Brancale A, Balzarini J, Naesens L, and McGuigan C (2013) Synthesis and biological evaluation of purine 29-fluoro-29-deoxyriboside ProTides as anti-influenza virus agents. ChemMedChem 8:415-425.
33. Morrey JD, Taro BS, Siddharthan V, Wang H, Smee DF, Christensen AJ, and Furuta Y (2008) Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral Res 80:377-379.
34. Moscona A (2008) Medical management of influenza infection. Annu Rev Med 59:397-413.
35. Moscona A (2009) Global transmission of oseltamivir-resistant influenza. N Engl J Med 360:953-956.
36. Osterhaus A, Fouchier R, and Rimmelzwaan G (2011) Towards universal influenza vaccines? Philos Trans R Soc Lond B Biol Sci 366:2766-2773.
37. Raman J, Sumathy K, Anand RP, and Balaram H (2004) A non-active site mutation in human hypoxanthine guanine phosphoribosyltransferase expands substrate specificity. Arch Biochem Biophys 427:116-122. (Pubitemid 38725920)
38. Rocha-Pereira J, Jochmans D, Dallmeier K, Leyssen P, Nascimento MS, and Neyts J (2012) Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem Biophys Res Commun 424:777-780.
39. Sakamoto K, Ohashi S, Yamazoe R, Takahashi K and Furuta Y. (2006) The inhibition of FMD virus excretion from the infected pigs by an antiviral agent, T-1105. FAO Report of the Research Group of the Standing Technical Committee of European Commission for the Control of Foot-and-Mouth Disease, Paphos, Cyprus, October 17-19, 2006. FAO Report Appendix 64, 418-424.
40. Schüttelkopf AW and van Aalten DM (2004) PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 60:1355-1363. (Pubitemid 41079731)
41. Shi W, Li CM, Tyler PC, Furneaux RH, Grubmeyer C, Schramm VL, and Almo SC (1999) The 2.0 A structure of human hypoxanthine-guanine phosphoribosyltransferase in complex with a transition-state analog inhibitor. Nat Struct Biol 6:588-593. (Pubitemid 29252842)
42. Sidwell RW, Barnard DL, Day CW, Smee DF, Bailey KW, Wong MH, Morrey JD, and Furuta Y (2007) Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 51:845-851. (Pubitemid 46355265)
43. Sleeman K, Mishin VP, Deyde VM, Furuta Y, Klimov AI, and Gubareva LV (2010) In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob Agents Chemother 54: 2517-2524.
44. Smee DF, Hurst BL, Egawa H, Takahashi K, Kadota T, and Furuta Y (2009) Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. J Antimicrob Chemother 64:741-746.
45. Stevaert A, Dallocchio R, Dessì A, Pala N, Rogolino D, Sechi M, and Naesens L (2013) Mutational analysis of the binding pockets of the diketo acid inhibitor L-742,001 in the influenza virus PA endonuclease. J Virol PMID: 23824822 [epub ahead of print].
46. Stout JT and Caskey CT (1985) HPRT: gene structure, expression, and mutation. Annu Rev Genet 19:127-148.
47. Streeter DG, Miller JP, Robins RK, and Simon LN (1977) The enzymic conversion of 1,2,4-triazole-3-carboxamide to ribavirin-5′-phosphate and its relationship to the proposed mechanism of action. Ann N Y Acad Sci 284:201-210. (Pubitemid 8110737)
48. Thomas CB, Arnold WJ, and Kelley WN (1973) Human adenine phosphoribosyltransferase. Purification, subunit structure, and substrate specificity. J Biol Chem 248:2529-2535.
49. Vanderlinden E, Göktas F, Cesur Z, Froeyen M, Reed ML, Russell CJ, Cesur N, and Naesens L (2010) Novel inhibitors of influenza virus fusion: structureactivity relationship and interaction with the viral hemagglutinin. J Virol 84:4277-4288.
50. Vanderlinden E, Vanstreels E, Boons E, ter Veer W, Huckriede A, Daelemans D, Van Lommel A, Ro{combining double acute accent}th E, Sztaricskai F, and Herczegh P et al. (2012) Intracytoplasmic trapping of influenza virus by a lipophilic derivative of aglycoristocetin. J Virol 86:9416-9431.
51. Willis RC, Carson DA, and Seegmiller JE (1978) Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line. Proc Natl Acad Sci USA 75:3042-3044. (Pubitemid 8395114)
52. Wu JZ, Larson G, Walker H, Shim JH, and Hong Z (2005) Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5′-nucleotidase II: Implications for ribavirin metabolism in erythrocytes. Antimicrob Agents Chemother 49:2164-2171. (Pubitemid 40734442)